Mylan Fights To Invalidate Novartis Blood Transfusion IP
Mylan SAS fought back allegations that its planned generic version of a blood transfusion drug made by Novartis AG would infringe Novartis' exclusive rights, arguing that the pharmaceutical giant wasn't entitled...To view the full article, register now.
Already a subscriber? Click here to view full article